Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro

Ganassin, Rayane; Merker, Carolin; Rodrigues, Mosar Corrêa; Guimarães, Nayara Felipe; Sodré, Carine Sampaio Cerqueira; da Silva Ferreira, Queila; da Silva, Sebastião William; Ombredane, Alicia Simalie; Joanitti, Graziella Anselmo; Py-Daniel, Karen Rapp; Zhang, Juan; Jiang, Cheng-Shi; de Morais, Paulo César; Mosiniewicz-Szablewska, Ewa; Suchocki, Piotr; Longo, João Paulo Figueiró; Meijer, Jan; Estrela-Lopis, Irina; de Azevedo, Ricardo Bentes; Muehlmann, Luis Alexandre

doi:10.6084/m9.figshare.5639959.v2

ianb_a_1408020_sm3496.docx (326.55 kB)

Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro

Version 2 2021-01-11, 13:40

Version 1 2017-11-28, 06:00

journal contribution

posted on 2021-01-11, 13:40 authored by Rayane Ganassin, Carolin Merker, Mosar Corrêa Rodrigues, Nayara Felipe Guimarães, Carine Sampaio Cerqueira Sodré, Queila da Silva Ferreira, Sebastião William da Silva, Alicia Simalie Ombredane, Graziella Anselmo Joanitti, Karen Rapp Py-Daniel, Juan Zhang, Cheng-Shi Jiang, Paulo César de Morais, Ewa Mosiniewicz-Szablewska, Piotr Suchocki, João Paulo Figueiró Longo, Jan Meijer, Irina Estrela-Lopis, Ricardo Bentes de Azevedo, Luis Alexandre Muehlmann

Nanocapsules (NCS-DOX) with an oily core of selol and a shell of poly(methyl vinyl ether-co-maleic anhydride) covalently conjugated to doxorubicin were developed. These nanocapsules are spherical, with an average hydrodynamic diameter of about 170 nm, and with negative zeta potential. NCS-DOX effectively co-delivered the selol and the doxorubicin into 4T1 cells and changed the intracellular distribution of DOX from the nuclei to the mitochondria. Moreover, a significantly increased cytotoxicity against 4T1 cells was observed, which is suggestive of additive or synergic effect of selol and doxorubicin. In conclusion, PVM/MA nanocapsules are suitable platforms to co-deliver drugs into cancer cells.